Structure Therapeutics Inc.

NASDAQ: GPCR · Healthcare · Biotechnology

PublicHQ South San Francisco, CA · San MateoCIK 0001888886Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 72DQ —GM —SS 58

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ listing tenure, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$141.2M

Employees

220

as of 2026-08-08

Market cap

$3.1B

as of 2026-08-08

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$141.2M-$141.2M2025

Operating income-$176.6M-$176.6M2025

Total assets$1.6B$1.6B2025

Liabilities$67.5M$67.5M2025

Equity$1.5B$1.5B2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Structure Therapeutics Inc.’s financial profile?

Structure Therapeutics Inc. earned -$141.2M in FY2025 net income.

Peers · Healthcare

Galera Therapeutics, Inc.——Vicore Pharma Holding AB——MBX Biosciences, Inc. Common Stock——Disc Medicine, Inc.——Kodiak Sciences Inc.——Trevi Therapeutics, Inc.——

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B86A Gilead Sciences, Inc.$29.4B87A Equinix, Inc.$9.2B74B Robinhood Markets, Inc.$4.5B67B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$052D

Key facts

CEORaymond C. Stevens

SectorHealthcare

IndustryBiotechnology

HeadquartersSouth San Francisco, CA

ExchangeNASDAQ: GPCR

Employees220

IPO date2023-02-03

Latest filings

10-Q2026-08-06 8-K2026-08-06 8-K2026-06-18 8-K2026-05-07 10-Q2026-05-07 DEF 14A2026-04-23 8-K2026-04-15 8-K2026-03-16

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.